EGFR and non-small cell lung carcinoma: • Adjuvant treatment for patients with EGFRm-NSCLC (exon 19 deletions or exon 21 L858R mutations)• 1L treatment for patients with EGFRm-NSCLC (exon 19 deletions or exon 21 L858R mutations)• Treatment for patients with metastatic EGFRm-NSCLC (T790M mutation), whose disease has progressed on or after another EGFR TKI